Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 3

Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine

Authors Ebrahim A Balbisi

Published 15 September 2006 Volume 2006:2(3) Pages 303—308

Ebrahim A Balbisi


St. John’s University, College Of Pharmacy & Allied Health Professions, Jamaica, New York, USA; Ambulatory Medicine, Queens Hospital Center, Jamaica, New York, USA


Abstract: Frovatriptan is an orally active 5-hydroxytryptamine (5-HT) receptor agonist which binds with high affinity to 5-HT1B and 5-HT1D receptors. Earlier clinical trials demonstrated that frovatriptan 2.5 mg is significantly more effective than placebo in the acute management of migraine and its associated symptoms. More recently, frovatriptan was shown to be effective in the management of menstrual migraine. The incidence of menstrual migraine in subjects receiving frovatriptan 2.5 mg twice daily during the six day perimenstrual period was 41% compared with 67% with placebo. Frovatriptan treatment is generally well tolerated. The most commonly reported adverse effects were dizziness, paresthesia, dry mouth, and fatigue. Pharmacologic studies demonstrated that frovatriptan is cerebroselective. Its selectivity for cerebral vessels lessens the potential for undesirable peripheral effects. Frovatriptan has a terminal deposition half-life of approximately 26 hours, which appears to be independent of age, gender, and renal function. This imparts that frovatriptan may be particularly well suited to patients with prolonged migraines and those who suffer migraine recurrence. Frovatriptan does not alter cytochrome P450 (CYP450) isoenzymes, as such it is unlikely to affect the metabolism of other drugs. No dosage adjustments are necessary based on age, renal, or mild to moderate hepatic impairment. Apart from its efficacy in the acute management of migraine, frovatriptan is an effective agent when used as either acute therapy or as intermittent prophylaxis therapy of menstrual migraines, particularly in women who do not respond to conventional therapies.


Keywords: migraine, menstrual migraine, 5-HT1B/1D, receptor agonists, pharmacokinetics, frovatriptan succinate

Download Article [PDF] 

Readers of this article also read:

Comorbidity and survival of Danish prostate cancer patients from 2000–2011: a population-based cohort study

Nguyen-Nielsen M, Nørgaard M, Jacobsen JB, Borre M, Thomsen RW, Søgaard M

Clinical Epidemiology 2013, 5:47-55

Published Date: 1 November 2013

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

Antiviral treatment in patients with hepatitis C virus-related cirrhosis awaiting liver transplantation

Pierluigi Toniutto, Carlo Fabris, Davide Bitetto, Ezio Fornasiere, Elisa Fumolo, et al

Therapeutics and Clinical Risk Management 2008, 4:599-603

Published Date: 6 June 2008

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

Omar S Din, Penella J Woll

Therapeutics and Clinical Risk Management 2008, 4:149-162

Published Date: 8 February 2008

Effect of patient-specific factors on weekly warfarin dose

Heather P Whitley, Joli D Fermo, Elinor CG Chumney, Walter Adam Brzezinski

Therapeutics and Clinical Risk Management 2007, 3:499-504

Published Date: 15 July 2007

Detection and remediation of medically urgent situations using telemedicine case management for older patients with diabetes mellitus

Roberto Izquierdo, Suzanne Meyer, Justin Starren, Robin Goland, Jeanne Teresi, et al

Therapeutics and Clinical Risk Management 2007, 3:485-489

Published Date: 15 July 2007

House dust mite control measures in the treatment of asthma

Gillian Vallance, Charles McSharry, Stuart Wood, Neil C Thomson

Therapeutics and Clinical Risk Management 2006, 2:347-354

Published Date: 15 December 2006

Voriconazole in the management of nosocomial invasive fungal infections

Javier Pemán, Miguel Salavert, Emilia Cantón, Isidro Jarque, Eva Romá, et al

Therapeutics and Clinical Risk Management 2006, 2:129-158

Published Date: 15 June 2006